New hope for aggressive lymphoma: drug MT-2111 under trial
Disease control
Ongoing
This study tests a drug called MT-2111 (loncastuximab tesirine) in people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The trial has two parts: first, to find a safe dose, and second…
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 23, 2026 23:19 UTC